Found 9 matching trials
Efficacy and Safety of Serplulimab in Combination With Bevacizumab and FOLFIRINOX or NALIRIFOX as Second-Line Therapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma PHASE2 This is an investigator-initiated, open-label, single-arm, phase II trial e...
Show More Location
Shanghai General Hospital
Learn More & Join Trial
Pilot Study of an Implantable Microdevice for In Situ Evaluation of Drug Response in Patients With Colorectal Liver Metastasis EARLY_PHASE1 Microdevices have been used to ascertain in vivo drug response, which can l...
Show More Learn More & Join Trial
Bevacizumab Plus Modiifed FOLFIRINOX in Ovarian, Fallopian Tube, or Primary Peritoneal Mucinous Carcinoma PHASE2 This research study is evaluating a modified FOLFIRINOX plus bevacizumab th...
Show More Location
Yonsei University Health System, Severance Hospital
Learn More & Join Trial
GLP-1 RA Plus SOC Treatment in First-line, Metastatic Pancreatic, Colorectal, or Hepatocellular Cancer EARLY_PHASE1 There is a growing number of patients diagnosed with gastrointestinal cance...
Show More Location
University of Arizona Cancer Center
Learn More & Join Trial
Evaluation of the Efficacy and the Safety of FOLFIRINOX3 Bevacizumab Treatment in Patients With Colorectal Cancer (FOLFIRINOX 3) PHASE1 In patients in progression after oxaliplatin and irinotecan, the study FOLF...
Show More Status
Active Not Recruiting
Location
Centre Georges François Leclerc
Learn More & Join Trial
Chemotherapies Associated With Targeted Therapies on the Resection Rate of Hepatic Metastases PHASE2 The main objective is to compare resection rates (R0 or R1) for hepatic met...
Show More Location
Centre Val d'Aurelle
Learn More & Join Trial
Ablative Therapy of Oligometastatic Tumor After Response to Conventional First Line Treatment N/A Advancements in systemic antineoplastic therapies have led to improved over...
Show More Learn More & Join Trial
Standard Systemic Therapy Combined With High/Low-dose Radiotherapy Plus Toripalimab for Metastatic Colorectal Cancer PHASE2 TORCH-M is a prospective, single-arm, two-cohort, investigator-initiated ph...
Show More Location
Fudan University Shanghai Cancer Center
Learn More & Join Trial
CPI-613 (Devimistat) in Combination With Modified FOLFIRINOX Plus Bevacizumab in Patients With Metastatic Colorectal Cancer PHASE1 Pre-clinical in vitro and in vivo data as well as early phase 1 clinical tr...
Show More Location
Multiple Locations
Learn More & Join Trial